Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Files Patent Infringement Suit Against GE Healthcare

NEW YORK (GenomeWeb News) – Invitrogen last week filed a patent infringement suit against GE Healthcare and other unnamed defendants for allegedly infringing six patents, four of which expired earlier this year.
Invitrogen said in its complaint filed in the US District Court for the Eastern District of Texas Tyler Division that GE Healthcare’s CyScript reverse transcriptase enzymes and kits infringe all six of the patents.
The US patents at issue are Nos. 6,610,522; 6,589,768; 6,063,608; 5,668,005; 5,244,797; 5,405,776. All but the last two expired in January.
Invitrogen is seeking an injunction against GE for sales of products that it believes currently are infringing the last two patents. It also is seeking royalties on past sales of products that it believes GE has infringed. Invitrogen alleged in the complaint that GE’s infringement was willful, which means that it would be entitled to triple damages.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.